Effect of recombinant human brain natriuretic peptide on treatment of refractory heart failure
重组人脑利钠肽对难治性心衰治疗效果的影响

摘要

目的 观察对难治性心衰采用重组人脑利钠肽治疗的效果。方法 在这项研究中，选择了2022年1月至12月间在我院接受治疗的60例难治性心衰患者。将患者随机分配为两组，每组各30人，一组作为对照组接受标准心力衰竭治疗，另一组为观察组，在标准治疗基础上加入重组人脑钠肽治疗。治疗周期为三个月，随后评估并比较两组患者心脏功能参数及不良反应发生情况。结果 观察组的心脏功能参数改善情况显著优于对照组，且这种差异在统计学上具有显著性（p＜0.05）；并且，观察组遇到的不良反应次数明显少于对照组，这一差异在统计上亦有显著性。（p＜0.05）。结论 重组人脑利钠肽在治疗难治性心衰方面具有显著效果，能够有效地改善患者的心功能，不良反应发生率较低，值得临床实践应用。

Abstract

Objective Observe the effect of recombinant human brain natriuretic peptide treatment on refractory heart failure.
Methods In this study, 60 patients with refractory heart failure who received treatment at our hospital between January and December 2022 were selected. Randomly assign patients to two groups, each with 30 people. One group will receive standard heart failure treatment as the control group, and the other group will be the observation group. Recombinant human brain natriuretic peptide therapy will be added to the standard treatment. The treatment period is three months, followed by evaluation and comparison of cardiac function parameters and incidence of adverse reactions between the two groups of patients.
Results The improvement of cardiac function parameters in the observation group was significantly better than that in the control group, and this difference was statistically significant (p<0.05); Moreover, the number of adverse reactions encountered by the observation group was significantly lower than that of the control group, and this difference was also statistically significant. (p<0.05).
Conclusion   Recombinant human brain natriuretic peptide has a significant effect in the treatment of refractory heart failure, which can effectively improve the heart function of patients with a low incidence of adverse reactions, and is worthy of clinical practice application.